Promising trial aims to spare throat cancer patients from unnecessary radiation
NCT ID NCT03215719
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether people with HPV-positive throat cancer can safely receive a lower dose of radiation if their tumor shrinks quickly during early treatment. About 120 participants will be monitored for 2 years to see if the reduced treatment still prevents cancer from coming back. The goal is to maintain effectiveness while reducing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
New York University School of Medicine
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Robotic surgery may spare throat cancer patients from chemo and radiation
- Can heat boost chemo? early trial tests thermotherapy for head and neck cancer
- Vaccine trains immune system to fight HPV-Positive head and neck tumors
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- Can less radiation be just as good for HPV throat cancer?